September 11th 2020
Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis.
September 9th 2020
Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.
August 17th 2020
Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials.
August 13th 2020
Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.
August 10th 2020
Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.
August 3rd 2020
Ruben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.
July 23rd 2020
Ruben A. Mesa, MD, discusses the potential clinical benefit of rechallenging with JAK inhibitor therapy in patients with myeloproliferative neoplasms.
July 17th 2020
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses recent data with momelotinib in myelofibrosis.
April 16th 2020
Ruben A. Mesa, MD, discusses advancements made in the treatment of patients with myeloproliferative neoplasms.
February 12th 2020
Ruben A. Mesa, MD, discusses new trials and agents in the pipeline in myelofibrosis.
January 28th 2020
Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.
January 16th 2020
Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.
August 16th 2019
Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the FDA approval of fedratinib (Inrebic) in myelofibrosis.
February 25th 2017
Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses how community oncologists can incorporate the NCCN Guideline for Myeloproliferative Neoplasms (MPNs) into clinical practice.
December 3rd 2016
Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs).
October 26th 2016
Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN guidelines for treatment of patients with myeloproliferative neoplasms (MPNs).
November 11th 2015
Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses advancements in polycythemia vera (PV).
August 14th 2015
Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses the intended patient population with myelofibrosis and low platelet counts for pacritinib.
June 8th 2015
Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study which examined pacribitinib as a treatment of myelofibrosis.
May 8th 2013
Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the mechanism of action of ruxolitinib in chronic myeloid leukemia.